CA2101241C - Ciprofloxacine encapsulee dans des liposomes - Google Patents

Ciprofloxacine encapsulee dans des liposomes

Info

Publication number: CA2101241C
Authority: CA; Canada
Prior art keywords: ciprofloxacin; mice; liposomes; lipids; antibiotic
Prior art date: 1993-07-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 2101241

Other languages

English (en)

Other versions

CA2101241A1 (fr

Inventor

Jonathan P. Wong

Vincent L. Dininno

John W. Cherwonogrodzky

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Minister of National Defence of Canada

Original Assignee

Minister of National Defence of Canada

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-23

Filing date

1993-07-23

Publication date

1998-12-22

1993-07-23 Application filed by Minister of National Defence of Canada filed Critical Minister of National Defence of Canada

1993-07-23 Priority to CA 2101241 priority Critical patent/CA2101241C/fr

1994-07-20 Priority to EP94305331A priority patent/EP0652008A1/fr

1995-01-24 Publication of CA2101241A1 publication Critical patent/CA2101241A1/fr

1998-12-22 Application granted granted Critical

1998-12-22 Publication of CA2101241C publication Critical patent/CA2101241C/fr

2013-07-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title claims abstract description 97
229960003405 ciprofloxacin Drugs 0.000 title claims abstract description 49
239000002502 liposome Substances 0.000 claims abstract description 25
150000002632 lipids Chemical class 0.000 claims abstract description 16
230000003115 biocidal effect Effects 0.000 claims abstract description 12
239000003242 anti bacterial agent Substances 0.000 claims description 12
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
238000000034 method Methods 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 9
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 5
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 5
235000012000 cholesterol Nutrition 0.000 claims description 5
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
238000009472 formulation Methods 0.000 claims description 3
238000004108 freeze drying Methods 0.000 claims description 3
239000008188 pellet Substances 0.000 claims description 3
239000011363 dried mixture Substances 0.000 claims 2
238000001035 drying Methods 0.000 claims 2
239000000725 suspension Substances 0.000 claims 2
239000002904 solvent Substances 0.000 claims 1
208000015181 infectious disease Diseases 0.000 abstract description 25
241000894006 Bacteria Species 0.000 abstract description 14
230000001225 therapeutic effect Effects 0.000 abstract description 6
239000003814 drug Substances 0.000 abstract description 5
229940079593 drug Drugs 0.000 abstract description 5
230000003834 intracellular effect Effects 0.000 abstract description 5
230000000844 anti-bacterial effect Effects 0.000 abstract description 4
210000004027 cell Anatomy 0.000 abstract description 3
230000008030 elimination Effects 0.000 abstract description 3
238000003379 elimination reaction Methods 0.000 abstract description 3
230000001010 compromised effect Effects 0.000 abstract description 2
238000010790 dilution Methods 0.000 abstract description 2
239000012895 dilution Substances 0.000 abstract description 2
210000001539 phagocyte Anatomy 0.000 abstract description 2
241000699670 Mus sp. Species 0.000 description 32
238000011282 treatment Methods 0.000 description 10
241000589602 Francisella tularensis Species 0.000 description 7
229940118764 francisella tularensis Drugs 0.000 description 7
238000001990 intravenous administration Methods 0.000 description 7
229940088710 antibiotic agent Drugs 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
150000007660 quinolones Chemical class 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229920001817 Agar Polymers 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000008272 agar Substances 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
244000052616 bacterial pathogen Species 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000011725 BALB/c mouse Methods 0.000 description 2
108020000946 Bacterial DNA Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
241000237537 Ensis Species 0.000 description 2
241000589601 Francisella Species 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
208000034784 Tularaemia Diseases 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
244000000056 intracellular parasite Species 0.000 description 2
210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
244000052769 pathogen Species 0.000 description 2
150000002960 penicillins Chemical class 0.000 description 2
238000007747 plating Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
229960000278 theophylline Drugs 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000518994 Conta Species 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
238000003794 Gram staining Methods 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
OEERIBPGRSLGEK-UHFFFAOYSA-N carbon dioxide;methanol Chemical compound OC.O=C=O OEERIBPGRSLGEK-UHFFFAOYSA-N 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
229940088516 cipro Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
229960004236 pefloxacin Drugs 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
230000003307 reticuloendothelial effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000008685 targeting Effects 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000001018 virulence Effects 0.000 description 1
238000003260 vortexing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 2101241 1993-07-23 1993-07-23 Ciprofloxacine encapsulee dans des liposomes Expired - Lifetime CA2101241C (fr)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
CA 2101241 CA2101241C (fr)	1993-07-23	1993-07-23	Ciprofloxacine encapsulee dans des liposomes
EP94305331A EP0652008A1 (fr)	1993-07-23	1994-07-20	Ciprofloxacin encapsulé en liposômes

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2101241 CA2101241C (fr)	1993-07-23	1993-07-23	Ciprofloxacine encapsulee dans des liposomes

Publications (2)

Publication Number	Publication Date
CA2101241A1 CA2101241A1 (fr)	1995-01-24
CA2101241C true CA2101241C (fr)	1998-12-22

Family

ID=4151982

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2101241 Expired - Lifetime CA2101241C (fr)	1993-07-23	1993-07-23	Ciprofloxacine encapsulee dans des liposomes

Country Status (2)

Country	Link
EP (1)	EP0652008A1 (fr)
CA (1)	CA2101241C (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9402845B2 (en)	2005-12-08	2016-08-02	Insmed Incorporated	Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9987227B2 (en)	2013-10-22	2018-06-05	Aradigm Corporation	Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
US10064882B2 (en)	2007-05-07	2018-09-04	Insmed Incorporated	Methods of treating pulmonary disorders with liposomal amikacin formulations
US10124066B2 (en)	2012-11-29	2018-11-13	Insmed Incorporated	Stabilized vancomycin formulations
US10238675B2 (en)	2014-05-15	2019-03-26	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US11571386B2 (en)	2018-03-30	2023-02-07	Insmed Incorporated	Methods for continuous manufacture of liposomal drug products
US12521345B1 (en)	2018-05-02	2026-01-13	Insmed Incorporated	Large-scale manufacturing methods for aminoglycosides
US12616708B2 (en)	2024-11-07	2026-05-05	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5972379A (en) *	1995-02-14	1999-10-26	Sequus Pharmaceuticals, Inc.	Liposome composition and method for administering a quinolone
US6221386B1 (en)	1996-03-08	2001-04-24	Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence	Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents
ES2130056B1 (es) *	1997-01-16	2000-02-01	Lipotec Sa	Un nuevo preparado farmaceutico para mejorar la biodisponibilidad oral de drogas de dificil absorcion.
US6667042B2 (en) *	2000-02-24	2003-12-23	Advancis Pharmaceutical Corp.	Fluroquinilone antibiotic product, use and formulation thereof
US6544555B2 (en)	2000-02-24	2003-04-08	Advancis Pharmaceutical Corp.	Antibiotic product, use and formulation thereof
US6565882B2 (en)	2000-02-24	2003-05-20	Advancis Pharmaceutical Corp	Antibiotic composition with inhibitor
US6991807B2 (en)	2000-02-24	2006-01-31	Advancis Pharmaceutical, Corp.	Antibiotic composition
US6541014B2 (en)	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
US20020197314A1 (en)	2001-02-23	2002-12-26	Rudnic Edward M.	Anti-fungal composition
AU2004258953B2 (en)	2003-07-21	2011-02-10	Shionogi, Inc.	Antibiotic product, use and formulation thereof
AU2004258949B2 (en)	2003-07-21	2011-02-10	Shionogi, Inc.	Antibiotic product, use and formulation thereof
JP2006528185A (ja)	2003-07-21	2006-12-14	アドバンシスファーマスーティカルコーポレイション	抗生物質製剤、その使用法及び作成方法
CA2535177A1 (fr)	2003-08-11	2005-02-24	Advancis Pharmaceutical Corporation	Pastille robuste
US8062672B2 (en)	2003-08-12	2011-11-22	Shionogi Inc.	Antibiotic product, use and formulation thereof
AU2004270170B2 (en)	2003-08-29	2011-01-27	Shionogi, Inc.	Antibiotic product, use and formulation thereof
CA2538064C (fr)	2003-09-15	2013-12-17	Advancis Pharmaceutical Corporation	Antibiotique, son utilisation et sa formulation
US20070224255A1 (en) *	2004-04-02	2007-09-27	Italfarmaco, S.A.	Liposomal Formulations
ES2254027B1 (es) *	2004-11-26	2007-07-01	Italfarmaco, S.A.	Formulaciones liposomales.
CA2572292A1 (fr)	2004-07-02	2006-02-09	Advancis Pharmaceutical Corporation	Comprime pour distribution par impulsion
US8357394B2 (en)	2005-12-08	2013-01-22	Shionogi Inc.	Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en)	2006-12-04	2014-07-15	Shionogi Inc.	Modified release amoxicillin products
US8299052B2 (en)	2006-05-05	2012-10-30	Shionogi Inc.	Pharmaceutical compositions and methods for improved bacterial eradication
US8119156B2 (en)	2006-10-24	2012-02-21	Aradigm Corporation	Dual action, inhaled formulations providing both an immediate and sustained release profile
US8268347B1 (en) *	2006-10-24	2012-09-18	Aradigm Corporation	Dual action, inhaled formulations providing both an immediate and sustained release profile
US8071127B2 (en)	2006-10-24	2011-12-06	Aradigm Corporation	Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2015156904A1 (fr)	2014-04-08	2015-10-15	Aradigm Corporation	Liposomes formant des nanocristaux de médicament suite à congélation-décongélation
CN116115576A (zh) *	2022-12-30	2023-05-16	成都市妇女儿童中心医院	一种功能化的载双药脂质体纳米粒子及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ201010A (en) *	1981-06-19	1986-02-21	Ciba Geigy Ag	The treatment of inflammation diseases using desferrioxamine
WO1991009616A1 (fr) *	1989-12-22	1991-07-11	Yale University	Antibiotiques a la quinolone encapsules dans des vesicules de lipides

1993
- 1993-07-23 CA CA 2101241 patent/CA2101241C/fr not_active Expired - Lifetime
1994
- 1994-07-20 EP EP94305331A patent/EP0652008A1/fr not_active Withdrawn

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10328071B2 (en)	2005-12-08	2019-06-25	Insmed Incorporated	Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9511082B2 (en)	2005-12-08	2016-12-06	Insmed Incorporated	Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9549925B2 (en)	2005-12-08	2017-01-24	Insmed Incorporated	Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9549939B2 (en)	2005-12-08	2017-01-24	Insmed Incorporated	Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US9402845B2 (en)	2005-12-08	2016-08-02	Insmed Incorporated	Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US10064882B2 (en)	2007-05-07	2018-09-04	Insmed Incorporated	Methods of treating pulmonary disorders with liposomal amikacin formulations
US10124066B2 (en)	2012-11-29	2018-11-13	Insmed Incorporated	Stabilized vancomycin formulations
US10471149B2 (en)	2012-11-29	2019-11-12	Insmed Incorporated	Stabilized vancomycin formulations
US9987227B2 (en)	2013-10-22	2018-06-05	Aradigm Corporation	Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
US10588918B2 (en)	2014-05-15	2020-03-17	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US11446318B2 (en)	2014-05-15	2022-09-20	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US10251900B2 (en)	2014-05-15	2019-04-09	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US10238675B2 (en)	2014-05-15	2019-03-26	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US10751355B2 (en)	2014-05-15	2020-08-25	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US10828314B2 (en)	2014-05-15	2020-11-10	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US11395830B2 (en)	2014-05-15	2022-07-26	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US10398719B2 (en)	2014-05-15	2019-09-03	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US12377114B2 (en)	2014-05-15	2025-08-05	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US12016873B2 (en)	2014-05-15	2024-06-25	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US12168021B2 (en)	2014-05-15	2024-12-17	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US12168022B2 (en)	2014-05-15	2024-12-17	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections
US12290600B2 (en)	2018-03-30	2025-05-06	Insmed Incorporated	Methods for continuous manufacture of liposomal drug products
US11571386B2 (en)	2018-03-30	2023-02-07	Insmed Incorporated	Methods for continuous manufacture of liposomal drug products
US12521345B1 (en)	2018-05-02	2026-01-13	Insmed Incorporated	Large-scale manufacturing methods for aminoglycosides
US12616708B2 (en)	2024-11-07	2026-05-05	Insmed Incorporated	Methods for treating pulmonary non-tuberculous mycobacterial infections

Also Published As

Publication number	Publication date
CA2101241A1 (fr)	1995-01-24
EP0652008A1 (fr)	1995-05-10

Legal Events

Date	Code	Title	Description
1995-09-14	EEER	Examination request

Publication	Publication Date	Title
CA2101241C (fr)	1998-12-22	Ciprofloxacine encapsulee dans des liposomes
Pinto-Alphandary et al.	2000	Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications
Conley et al.	1997	Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice
Magallanes et al.	1993	Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis
Chadha et al.	2017	Liposome loaded phage cocktail: enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections
Beaulac et al.	1998	In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria.
Swenson et al.	1988	Preparation and use of liposomes in the treatment of microbial infections
US5662929A (en)	1997-09-02	Therapeutic liposomal formulation
Cynamon et al.	1989	Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice
Swenson et al.	1990	Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin
Storm et al.	1998	Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system.
Bakker-Woudenberg	2002	Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci
Desiderio et al.	1983	Intraphagocytic killing of Salmonella typhimurium by liposome-encapsulated cephalothin
JPS60502205A (ja)	1985-12-19	単一相中で調製された脂質小胞類
Alving	1988	Macrophages as targets for delivery of liposome-encapsulated antimicrobial agents
US6613352B2 (en)	2003-09-02	Low-rigidity liposomal formulation
Fierer et al.	1990	Successful treatment using gentamicin liposomes of Salmonella dublin infections in mice
Tadakuma et al.	1985	Treatment of experimental salmonellosis in mice with streptomycin entrapped in liposomes
Bakker-Woudenberg et al.	1986	Effect of liposome-entrapped ampicillin on survival of Listeria monocytogenes in murine peritoneal macrophages
Brook	1989	Pathogenicity of the Bacteroides fragilis group
Hamilton et al.	1978	Synergistic infection with murine cytomegalovirus and Pseudomonas aeruginosa in mice
US5834424A (en)	1998-11-10	Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
Fresta et al.	1995	Intracellular accumulation of ofloxacin-loaded liposomes in human synovial fibroblasts
Vitas et al.	1997	Protective effect of liposomal gentamicin against systemic acute murine brucellosis
CN102309448B (zh)	2014-07-09	一种肺部给药的环丙沙星药用组合物及其制备方法